These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20689934)

  • 1. Statistical analysis plan of PROWESS SHOCK study.
    ; Thompson BT; Ranieri VM; Finfer S; Barie PS; Dhainaut JF; Douglas IS; Gårdlund B; Marshall JC; Rhodes A
    Intensive Care Med; 2010 Nov; 36(11):1972-3. PubMed ID: 20689934
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis.
    Kalil AC; Florescu DF
    Crit Care; 2013 Jul; 17(4):167. PubMed ID: 23826709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 4. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 5. [Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
    Montravers P; Blaise M
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():38-9. PubMed ID: 15359941
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating sepsis.
    Wenzel RP
    N Engl J Med; 2002 Sep; 347(13):966-7. PubMed ID: 12324551
    [No Abstract]   [Full Text] [Related]  

  • 7. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of sepsis.
    Mackenzie AF; Bartelink AK
    N Engl J Med; 2007 Mar; 356(11):1179; author reply 1181-2. PubMed ID: 17361493
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting the coagulation cascade in sepsis: did we find the "magic bullet"?
    Mathiak G; Neville LF; Grass G
    Crit Care Med; 2003 Jan; 31(1):310-1. PubMed ID: 12545036
    [No Abstract]   [Full Text] [Related]  

  • 10. New mode of intervention in sepsis treatment.
    Foubister V
    Drug Discov Today; 2003 Jul; 8(14):610-2. PubMed ID: 12867140
    [No Abstract]   [Full Text] [Related]  

  • 11. Human recombinant activated protein C for severe sepsis.
    Martí-Carvajal AJ; Solà I; Lathyris D; Cardona AF
    Cochrane Database Syst Rev; 2012 Mar; (3):CD004388. PubMed ID: 22419295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Criteria for use of drotrecogin alfa.
    Jacobi J
    Am J Health Syst Pharm; 2004 Jan; 61(2):203-4; author reply 204-5. PubMed ID: 14750407
    [No Abstract]   [Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 14. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 15. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
    Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
    Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
    Levi M
    Crit Care Med; 2003 Mar; 31(3):984-5. PubMed ID: 12627023
    [No Abstract]   [Full Text] [Related]  

  • 17. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant human activated protein C sentenced to the death of a thousand cuts?
    O'Brien JM
    Crit Care Med; 2007 Jun; 35(6):1609-10. PubMed ID: 17522532
    [No Abstract]   [Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.